Javascript must be enabled to continue!
Oesophageal cancer is an uncommon cause of death in patients with Barrett's oesophagus.
View through CrossRef
BACKGROUND: Barrett's oesophagus carries a 30-fold to 40-fold increased risk of oesophageal cancer. It is unknown whether endoscopic surveillance programmes reduce mortality from oesophageal cancer. METHODS: A cohort study was undertaken of all 166 patients in whom the diagnosis Barrett's oesophagus had been established between 1973 and 1986. RESULTS: One hundred and fifty five of 166 patients could be traced (93%). During a mean follow up of 9.3 years (amounting to 1440 patient years) eight patients had developed oesophageal cancer at random intervals (one case in 180 patient years). All but one of the tumours were diagnosed at endoscopy for symptoms, three in the stage of carcinoma in situ. Risk factors for the development of oesophageal cancer were extensive Barrett's oesophagus exceeding 10 cm (p = 0.02) and Barrett's ulcer at the time of intake (p = 0.009). Seventy six patients were alive; three had undergone surgery for oesophageal cancer and were without recurrence respectively, 12.8 years, 12.1 years, and 7 months postoperatively. Seventy nine patients had died; five of them had developed oesophageal cancer, but in only two cases this had been the cause of death (2.5%). CONCLUSIONS: Oesophageal cancer is an uncommon cause of death in patients with Barrett's oesophagus. The patients of this cohort would not have benefited from an endoscopic surveillance programme.
Title: Oesophageal cancer is an uncommon cause of death in patients with Barrett's oesophagus.
Description:
BACKGROUND: Barrett's oesophagus carries a 30-fold to 40-fold increased risk of oesophageal cancer.
It is unknown whether endoscopic surveillance programmes reduce mortality from oesophageal cancer.
METHODS: A cohort study was undertaken of all 166 patients in whom the diagnosis Barrett's oesophagus had been established between 1973 and 1986.
RESULTS: One hundred and fifty five of 166 patients could be traced (93%).
During a mean follow up of 9.
3 years (amounting to 1440 patient years) eight patients had developed oesophageal cancer at random intervals (one case in 180 patient years).
All but one of the tumours were diagnosed at endoscopy for symptoms, three in the stage of carcinoma in situ.
Risk factors for the development of oesophageal cancer were extensive Barrett's oesophagus exceeding 10 cm (p = 0.
02) and Barrett's ulcer at the time of intake (p = 0.
009).
Seventy six patients were alive; three had undergone surgery for oesophageal cancer and were without recurrence respectively, 12.
8 years, 12.
1 years, and 7 months postoperatively.
Seventy nine patients had died; five of them had developed oesophageal cancer, but in only two cases this had been the cause of death (2.
5%).
CONCLUSIONS: Oesophageal cancer is an uncommon cause of death in patients with Barrett's oesophagus.
The patients of this cohort would not have benefited from an endoscopic surveillance programme.
Related Results
Impact of gastro-oesophageal reflux on microRNA expression, location and function
Impact of gastro-oesophageal reflux on microRNA expression, location and function
Abstract
Background
Ulceration of the oesophageal squamous mucosa (ulcerative oesophagitis) is a pathological manifestation of gastro-oesophageal...
Oesophageal atresia: Are “long gap” patients at greater anesthetic risk?
Oesophageal atresia: Are “long gap” patients at greater anesthetic risk?
SummaryBackgroundLong gap oesophageal atresia occurs in approximately 10% of all oesophageal atresia infants and surgical repair is often difficult with significant postoperative c...
Upregulation of Twist in oesophageal squamous cell carcinoma is associated with neoplastic transformation and distant metastasis
Upregulation of Twist in oesophageal squamous cell carcinoma is associated with neoplastic transformation and distant metastasis
Background:The antiapoptotic and epithelial–mesenchymal transition activities of Twist have been implicated in the neoplastic transformation and the development of metastasis, resp...
Nutcracker oesophagus: a double‐blind, placebo‐controlled, cross‐over study of the effects of lansoprazole
Nutcracker oesophagus: a double‐blind, placebo‐controlled, cross‐over study of the effects of lansoprazole
SummaryBackground : Nutcracker oesophagus is characterized by high‐amplitude oesophageal contractions. Recent data have shown a high prevalence of gastro‐oesophageal acid reflux in...
Increased risk of gastro-oesophageal cancers among married couples: Data from the Ardabil Cancer Registry (ACR) in Northwest of Iran, 2002-2016
Increased risk of gastro-oesophageal cancers among married couples: Data from the Ardabil Cancer Registry (ACR) in Northwest of Iran, 2002-2016
Abstract
Background: The study of cancer in spouses may play an important role in the assessment of cancer etiology. This study aims to evaluate the risk of gastro-oesophag...
X-ray-guided self-expandable metal stent (SEMS) implantation in oesophageal malignancy as an alternative treatment
X-ray-guided self-expandable metal stent (SEMS) implantation in oesophageal malignancy as an alternative treatment
<b><br>Indroduction:</b> Significant dysphagia, aspiration pneumonia, and impossible oral nutrition in patients with unresectable or recurrent gastroesophageal ma...
International variation in oesophageal and gastric cancer survival 2012–2014: differences by histological subtype and stage at diagnosis (an ICBP SURVMARK-2 population-based study)
International variation in oesophageal and gastric cancer survival 2012–2014: differences by histological subtype and stage at diagnosis (an ICBP SURVMARK-2 population-based study)
Objective
To provide the first international comparison of oesophageal and gastric cancer survival by stage at diagnosis and histological subtype across high-in...
Edoxaban and Cancer-Associated Venous Thromboembolism: A Meta-analysis of Clinical Trials
Edoxaban and Cancer-Associated Venous Thromboembolism: A Meta-analysis of Clinical Trials
Abstract
Introduction
Cancer patients face a venous thromboembolism (VTE) risk that is up to 50 times higher compared to individuals without cancer. In 2010, direct oral anticoagul...

